Having picked up a pipeline of oncology drugs as part of a merger last year, NAYA Biosciences is reverting back to its original focus of fertility and ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

“We were probably one of the lucky few that was able to go out last fall and have such a strong and successful IPO,” Bicara ...

Johnson & Johnson MedTech reported that it has completed the first U.S. clinical cases of its Ottava surgical robot, with a ...

Ironwood Pharmaceuticals has been left considering its options after the FDA demanded another phase 3 trial before it will ...

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

The U.K. is rolling out new regulations meant to reduce red tape for clinical studies and boost the nation’s role in international trials.

CTI grew from a Cincinnati startup to a global leader in clinical research. CEO Tim Schroder shares insights on its success ...

| Discover how AI and RWD are transforming drug development by optimizing clinical trial protocols, enhancing recruitment, ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...